Cannabinoid receptors and their ligands: ligand-ligand and ligand-receptor modeling approaches
- PMID:16596777
Cannabinoid receptors and their ligands: ligand-ligand and ligand-receptor modeling approaches
Abstract
The cannabinoid CB1 and CB2 receptors belong to the class A, rhodopsin-like family of GPCRs. Antagonists for each receptor sub-type, as well as four structural classes of agonists that bind to both receptors, have been identified. An extensive amount of structure-activity relationship information (SAR) has been developed for agonists and antagonists that bind at CB1, while the SAR of CB2 ligands is only now emerging in the literature. This chapter focuses both on recent CB1 and CB2 SAR and on the pharmacophores for ligand recognition at the CB1 receptor that have been developed using ligand-ligand or ligand-receptor approaches. In a ligand-ligand approach, the structure of the binding site of the ligand is not directly considered. This approach is an attempt to infer information about the macromolecular binding site, and/or modes of binding interactions from a correlation between experimentally determined biological activities and the structural and electronic features of a series of small molecules. In a ligand-receptor approach, cannabinoid (CB) receptor models are probed for ligand binding sites and binding sites can be screened using energetic criteria, as well as ligand SAR and the CB mutation literature. This chapter discusses the factors that control the quality of the results emanating from each of these approaches and identifies areas of agreement and of disagreement in the existing CB literature. Challenges for future SAR and pharmacophore development are also identified.
Similar articles
- Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors.Reggio PH.Reggio PH.Curr Pharm Des. 2003;9(20):1607-33. doi: 10.2174/1381612033454577.Curr Pharm Des. 2003.PMID:12871061Review.
- Indoles and related compounds as cannabinoid ligands.Manera C, Tuccinardi T, Martinelli A.Manera C, et al.Mini Rev Med Chem. 2008 Apr;8(4):370-87. doi: 10.2174/138955708783955935.Mini Rev Med Chem. 2008.PMID:18473928Review.
- Structural requirements for cannabinoid receptor probes.Thakur GA, Nikas SP, Li C, Makriyannis A.Thakur GA, et al.Handb Exp Pharmacol. 2005;(168):209-46. doi: 10.1007/3-540-26573-2_7.Handb Exp Pharmacol. 2005.PMID:16596776Review.
- CB1 and CB2 cannabinoid receptor binding studies based on modeling and mutagenesis approaches.Ortega-Gutiérrez S, López-Rodríguez ML.Ortega-Gutiérrez S, et al.Mini Rev Med Chem. 2005 Jul;5(7):651-8. doi: 10.2174/1389557054368754.Mini Rev Med Chem. 2005.PMID:16026311Review.
- Ligand-ligand and ligand-receptor approaches to modeling the cannabinoid CB1 and CB2 receptors: achievements and challenges.Reggio PH.Reggio PH.Curr Med Chem. 1999 Aug;6(8):665-83.Curr Med Chem. 1999.PMID:10469885Review.
Cited by
- Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.Morales P, Gómez-Cañas M, Navarro G, Hurst DP, Carrillo-Salinas FJ, Lagartera L, Pazos R, Goya P, Reggio PH, Guaza C, Franco R, Fernández-Ruiz J, Jagerovic N.Morales P, et al.J Med Chem. 2016 Jul 28;59(14):6753-6771. doi: 10.1021/acs.jmedchem.6b00397. Epub 2016 Jul 6.J Med Chem. 2016.PMID:27309150Free PMC article.
- Dose-dependent teratogenicity of the synthetic cannabinoid CP-55,940 in mice.Gilbert MT, Sulik KK, Fish EW, Baker LK, Dehart DB, Parnell SE.Gilbert MT, et al.Neurotoxicol Teratol. 2016 Nov-Dec;58:15-22. doi: 10.1016/j.ntt.2015.12.004. Epub 2015 Dec 18.Neurotoxicol Teratol. 2016.PMID:26708672Free PMC article.
- Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors.Bauer M, Chicca A, Tamborrini M, Eisen D, Lerner R, Lutz B, Poetz O, Pluschke G, Gertsch J.Bauer M, et al.J Biol Chem. 2012 Oct 26;287(44):36944-67. doi: 10.1074/jbc.M112.382481. Epub 2012 Sep 5.J Biol Chem. 2012.PMID:22952224Free PMC article.
- Chromenopyrazoles: non-psychoactive and selective CB₁ cannabinoid agonists with peripheral antinociceptive properties.Cumella J, Hernández-Folgado L, Girón R, Sánchez E, Morales P, Hurst DP, Gómez-Cañas M, Gómez-Ruiz M, Pinto DC, Goya P, Reggio PH, Martin MI, Fernández-Ruiz J, Silva AM, Jagerovic N.Cumella J, et al.ChemMedChem. 2012 Mar 5;7(3):452-63. doi: 10.1002/cmdc.201100568. Epub 2012 Feb 2.ChemMedChem. 2012.PMID:22302767Free PMC article.
- Endogenous lipid activated G protein-coupled receptors: emerging structural features from crystallography and molecular dynamics simulations.Hurst DP, Schmeisser M, Reggio PH.Hurst DP, et al.Chem Phys Lipids. 2013 Apr;169:46-56. doi: 10.1016/j.chemphyslip.2013.01.009. Epub 2013 Feb 26.Chem Phys Lipids. 2013.PMID:23485612Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Miscellaneous